Effects of inhibiting protein arginine methyltransferases (PRMTs) on immunomodulatory gene expression using in vitro breast cancer models

This study investigated the effects of inhibiting protein arginine methyltransferases (PRMTs) on immunomodulatory gene expression using in vitro breast cancer models. Breast cancer cell lines (MDA-MB-231 and MCF-7) and a non-tumorigenic breast cell line (MCF-10A) were treated with different concentrations of PRMT1 or PRMT5 inhibitors, with DMSO used as a control. Cell viability was assessed using the Alamar Blue assay, and a scratch assay was performed to evaluate the migratory potential of MDA-MB-231 cells after treatment. Gene expression levels of cytotoxic T lymphocyte antigen 4 (CTLA-4), programmed death protein 1 (PD-1), programmed death ligand 1 (PD-L1), lymphocyte activation gene-3 (LAG-3), and T cell immunoglobulin and mucin domain-containing protein 3 (TIM-3) were measured using quantitative PCR (qPCR). The data include cell viability percentages for MDA-MB-231, MCF-7, and MCF-10A cells under the different treatments, scratch assay images of treated MDA-MB-231 cells, RNA quality control results, and comparisons of immunomodulatory gene expression across cell lines and treatments.